Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal
Genentech chief dealmaker James Sabry has found the latest addition for their early-stage cancer drug pipeline at South Korea’s Hanmi. The big Roche subsidiary has licensed the global rights — outside of Korea — to HM95573, a pan-RAF inhibitor now in Phase I.
Hanmi is getting $80 million upfront, $830 million in milestones and a chance at partnering with one of the highest profile teams in cancer drug development. And Genentech adds another select program from a business development team that likes to keep a focused approach on filling particular gaps in a busy pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.